ATCC ATCC Logo 0
Human oral squamous carcinoma cell.

Cell Symposium: Overcoming Therapy Resistance in Cancer

Virtual Event

November 08, 2021 - November 10, 2021

The Cell Symposium: Overcoming Therapy Resistance in Cancer virtual event provides a robust platform for cancer researchers to discuss the mechanisms underlying therapy resistance in cancer, ways to overcome drug resistance, and approaches for personalized medicine. At this event, we showcased our latest 2-D and 3-D patient-derived cancer models, EMT and THP-1 reporter cell lines, human primary cells, cancer panels, immuno-oncology research tools, and more! We also presented a workshop on advanced drug-resistant cell models for cancer therapeutic resistance studies. Explore our resources below to see how we can collaborate on your next project!

Did you miss us at the event and want to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.


Contact us

Read our white papers

Drug Resistance in Cancer: Mechanisms and Models

Learn about the development of drug-resistant cancer models via precise genetic engineering and explore their applications in mechanistic studies and therapeutic screening.

Read the white paper

CRISPR/Cas9-engineered Cancer Models

Learn about the use of CRISPR/Cas9 in engineering cell models that mimic specific cancer genotypes and phenotypes found in clinical tumor samples.

Read the white paper

Check out our workshop

Advanced Drug-resistant Cell Models for Cancer Therapeutic Resistance Studies

November 10, 2021
10:30 AM – 10:55 AM ET

Fang Tian, PhD, Principal Scientist, Head of Cell Biology R&D group, ATCC

In this workshop, we highlighted how state-of-the-art ATCC drug-resistant cancer cell models created by CRISPR gene editing technology can facilitate the discovery of new types of therapeutics that overcomes drug resistance.

Access the presentation

Human Cancer Models Initiative

ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2D and 3D patient-derived in vitro cancer models, including organoids. ATCC is committed to making available a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.

Find next-generation models
Fluorescent blue and green spheres of leukemic cells.

Credible models for immuno-oncology research

Discover now

Contact us today!

Your ATCC sales representative stands ready to discuss your research needs and provide you with personalized care in sourcing reference materials, scheduling services, managing custom requests, and providing sales quotes. Please complete our form to let us know how we can help, and we will start working on your needs right away.





We will not share your information outside of our distributors network and solely use it to send relevant communications.
Your form has been successfully submitted